DrugPatentWatch Database Preview
Details for Biologics License Application: 125276
» See Plans and Pricing
Summary for BLA: 125276
| Tradename: | ACTEMRA |
| Applicant: | Genentech |
| Ingredient: | tocilizumab |
| Patents: | 79 |
| Approval Date: | Jan 08, 2010 |
| Suppliers: see list | 1 |
Pharmacology for BLA: 125276
| Drug Class | Interleukin-6 Receptor Antagonist |
| Mechanism of Action | Interleukin 6 Receptor Antagonists |
US Patents for BLA: 125276
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) | 2034-01-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | 2039-02-26 | RX | search | ||
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | CureVac AG (Tubingen, DE) | 2032-02-15 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
